What are the Australian guidelines for treating mild allergic rhinitis in children?

Pediatric Mild Allergic Rhinitis: Australian Guidelines

For children with mild allergic rhinitis in Australia, intranasal corticosteroids are the most effective first-line treatment, with second-generation oral antihistamines or intranasal antihistamines serving as alternative options for mild intermittent symptoms dominated by sneezing and itching. 1, 2

First-Line Treatment for Mild Disease

Intranasal corticosteroids remain the gold standard even for mild allergic rhinitis because they control all four major nasal symptoms (congestion, rhinorrhea, sneezing, itching) more effectively than any other medication class. 1, 2, 3

Age-Appropriate Intranasal Corticosteroid Selection

• Children ≥2 years: Mometasone furoate (Nasonex) 1 spray per nostril daily (100 mcg total) or triamcinolone acetonide (Nasacort) 1 spray per nostril daily for ages 2-5 years 2
• Children ≥4 years: Fluticasone propionate (Flonase) 1 spray per nostril daily (100 mcg total) 2
• Children ≥6 years: Budesonide (Rhinocort) becomes an additional option 2

Critical Safety Points for Pediatric Use

• Fluticasone propionate, mometasone furoate, and budesonide show no effect on growth at recommended doses compared to placebo, even at twice the recommended doses 2, 4
• Avoid beclomethasone dipropionate in children—it is the only intranasal steroid associated with growth suppression at standard doses 2, 4
• No hypothalamic-pituitary-adrenal axis suppression occurs at recommended pediatric doses 2, 4
• Symptom relief begins within 12 hours, but maximal efficacy requires several days to weeks of continuous daily use 2, 3

Alternative Options for Mild Intermittent Symptoms

For children with mild intermittent allergic rhinitis where sneezing and itching predominate (rather than congestion), second-generation oral antihistamines or intranasal antihistamines may be used as first-line therapy. 1, 3

Oral Antihistamine Options

• Second-generation antihistamines (cetirizine, loratadine, fexofenadine) are effective for sneezing, itching, and rhinorrhea with minimal sedation 5, 3
• Avoid first-generation antihistamines (diphenhydramine) due to sedation, performance impairment, and anticholinergic effects 3
• Oral antihistamines are less effective for nasal congestion than intranasal corticosteroids 2, 3

Intranasal Antihistamine Options

• Intranasal antihistamines (azelastine) are equal or superior to oral second-generation antihistamines for seasonal allergic rhinitis 3, 4
• They have a unique advantage of providing clinically significant relief of nasal congestion, unlike oral antihistamines 3

Proper Administration Technique

Teaching correct spray technique is essential to maximize efficacy and minimize side effects:

• Prime the bottle before first use and shake before each administration 2
• Have the child blow their nose prior to spraying 2
• Keep the head upright during administration 2
• Use the opposite hand for each nostril (contralateral technique)—this directs spray away from the nasal septum and reduces epistaxis risk by fourfold 2, 4
• Breathe in gently during spraying; do not close the opposite nostril 2
• If using nasal saline irrigation, perform it before the steroid spray 2

Common Side Effects and Management

• Epistaxis (nosebleeds) is the most common side effect, typically presenting as blood-tinged secretions in 4-8% of patients 2, 4
• Proper contralateral spray technique dramatically reduces epistaxis risk 2, 4
• Other mild side effects include headache, pharyngitis, nasal burning/irritation, nausea, and cough 2
• Local side effects such as nasal septal perforation are rare and preventable with proper technique 2

Medications to Avoid in Mild Allergic Rhinitis

• Do not use leukotriene receptor antagonists (montelukast) as primary therapy—they are markedly less effective than intranasal corticosteroids 1, 5, 3
• Limit topical decongestants to 3 days maximum to prevent rebound congestion (rhinitis medicamentosa) 3, 4
• Avoid oral decongestants in children <3 years due to adverse effects outweighing benefits 3
• Do not prescribe antibiotics for allergic rhinitis—they are ineffective and contribute to antimicrobial resistance 3

Treatment Duration and Monitoring

• Minimum trial of 8-12 weeks is recommended to properly assess therapeutic benefit 2, 4
• Counsel families that full benefit may not be evident for the first 2 weeks 2, 4
• For seasonal allergic rhinitis, start treatment before the pollen season begins for optimal prophylaxis 3
• Continuous daily treatment is more effective than intermittent use for perennial allergic rhinitis 3
• Long-term use is safe—no systemic effects, growth suppression, or HPA axis suppression at recommended doses 2, 4

When to Escalate or Refer

• If symptoms remain inadequately controlled after 2-3 weeks of intranasal corticosteroid alone, add an intranasal antihistamine (azelastine) rather than an oral antihistamine 1, 5, 4
• The combination of fluticasone + azelastine provides >40% relative improvement compared to either agent alone 1, 5, 4
• Do not add oral antihistamines to intranasal corticosteroids—multiple high-quality trials show no additional benefit for nasal symptoms 1, 5, 4
• Refer for specific IgE testing (skin prick or serum) when empiric therapy fails, diagnosis is uncertain, or allergen identification is needed for avoidance or immunotherapy 3

Environmental Control Measures

• Identify specific allergen triggers through testing when appropriate 3
• Implement targeted avoidance strategies: pet removal, high-efficiency air filtration, allergen-impermeable bedding covers, acaricide treatments 3
• Address non-allergen irritants: tobacco smoke, strong odors, temperature/humidity extremes 3
• Advise parents not to smoke—maternal smoking during pregnancy and environmental tobacco smoke worsen allergic disease 6

Common Pitfalls to Avoid

• Do not assume combination therapy is superior—intranasal corticosteroid monotherapy is often sufficient and more cost-effective for mild disease 1, 5
• Do not delay treatment awaiting allergy testing—start intranasal corticosteroids immediately based on clinical diagnosis 3, 4
• Do not prescribe beclomethasone dipropionate in children—it is the only intranasal steroid with documented growth suppression risk 2, 4
• Do not use fluticasone propionate in children <4 years—select age-appropriate alternatives like mometasone or triamcinolone 2
• Ensure families understand that intranasal corticosteroids are maintenance therapy, not rescue therapy—they should not be discontinued when symptoms improve 2